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Mounting evidence indicates that alterations of AKT signalling play important roles in cancer development. An earlier study
discovered an oncogenic AKT1 gene mutation (AKT1 E17K) in breast, colorectal and ovarian cancers. The aim of this study was to see
whether the AKT1 E17K mutation is common in breast, colorectal, lung, gastric and hepatocellular carcinomas and acute leukaemias.
We analysed the presence of the AKT1 E17K mutation in 731 cancer tissues by a single-strand conformation polymorphism assay. In
addition, we analysed the corresponding sequences of AKT1 E17K in AKT2 and AKT3 genes. Overall, we detected the four AKT1 E17K
mutations in the breast cancers (4/93; 4.3%), but none in other cancers. There was no AKT2 or AKT3 mutation in the cancers. This
study demonstrated that the AKT1 E17K mutation occurs in breast cancers at a low frequency, and that it is rare in other common
cancers, including colorectal, lung, gastric and hepatocellular carcinomas and acute leukaemias. Despite the confirmed oncogenic
function of the AKT1 E17K, the rare incidences of the mutation suggest that it may not play a crucial role in the development of the
most common types of human cancers.
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Protein kinases regulate cell signalling pathways mediating a
number of processes in cell proliferation, differentiation and
survival (Gschwind et al, 2004). AKT1 (also known as protein
kinase B) is a subfamily of serine/threonine protein kinases, and
the AKT genes are the mammalian equivalent of murine viral
oncogene v-akt (Testa and Bellacosa, 2001). There are three
isoforms of the AKT (AKT1, AKT2 and AKT3), and each AKT
member contains an N-terminal pleckstrin homology (PH)
domain, a short a-helical linker and a C-terminal kinase domain
(Testa and Bellacosa, 2001). AKTs are major downstream targets of
growth factor receptors that signal through phosphatidylinositol 3-
kinase (Testa and Bellacosa, 2001). Mounting evidence exists that
activation of AKT proteins is important in cancer development
(Muise-Helmericks et al, 1998; Dimmeler et al, 1999; Khwaja, 1999;
Ozes et al, 1999; Mende et al, 2001; Wei et al, 2001). PTEN inhibits
AKT activation and works as a tumour suppressor (Testa and
Bellacosa, 2001). Inactivating mutation of PTEN and activating
mutation of PIK3CA have been detected in many human cancers
and have been known as major activating mechanisms of AKT-
signalling pathway in cancers (Testa and Bellacosa, 2001; Samuels
et al, 2004). By contrast, activating mutation of AKT genes has not
been widely reported in human cancers.
Recently, a research group discovered a recurrent somatic
mutation of AKT1 gene in human breast, colorectal and ovarian
cancers (Carpten et al, 2007). The AKT1 mutation was a missense
mutation that substituted an amino acid (E17K) in the PH domain
of AKT1. The AKT1 E17K mutation was found in 5 out of 61 (8.2%)
breast cancers, 3 out of 51 (5.9%) colorectal cancers and 1 out of 50
(2.0%) ovarian cancers (Carpten et al, 2007). The E17K mutation
was mutually exclusive with respect to PIK3CA mutation and loss
of PTEN expression (Carpten et al, 2007). Functionally, the AKT1
E17K mutation stimulates AKT signalling, induces cellular
transformation and produces leukaemia in mice, strongly suggesting
that this mutation may play a crucial role in cancer development
(Carpten et al, 2007).
To further characterise the AKT1 E17K mutation in human
cancers, the following questions were investigated in this study:
(a) whether human cancer tissues from various histologic origins
have the AKT1 E17K mutation; (b) whether there is any ethnic
difference of the AKT1 E17K mutation incidence in breast and
colorectal cancers; and (c) whether any corresponding mutation of
AKT1 E17K occurs in AKT2 or AKT3 genes.
MATERIALS AND METHODS
We analysed AKT1 for the detection of the AKT1 E17K mutation in
methacarn-fixed tissues of 93 breast ductal carcinomas, 104
colorectal adenocarcinomas, 180 gastric adenocarcinomas, 68
hepatocellular carcinomas and 157 non-small cell lung cancers
(NSCLCs), and fresh non-fixed fresh tissues of 129 adulthood acute
leukaemias by polymerase chain reaction (PCR)-single strand
conformation polymorphism (SSCP) analysis. All of the cancer
patients were Korean. Approval for this study was obtained from
the Institutional Review Board of the Catholic University of Korea,
College of Medicine. The gastric carcinomas consisted of 40 early
and 140 advanced gastric carcinomas. The breast carcinomas
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sconsisted of 15 ductal carcinomas in situ and 78 invasive ductal
carcinomas. The NSCLCs consisted of 74 adenocarcinomas, 70
squamous cell carcinomas, 3 adenosquamous carcinomas and 10
large-cell carcinomas. The acute leukaemias consisted of 95 acute
myelogenous leukaemia, 33 acute lymphoblastic leukaemia (ALL)
(29 B-ALL and 4 T-ALL) and 1 undifferentiated acute leukaemia.
For the solid tumours, malignant cells and normal cells were
selectively procured from haematoxylin and eosin-stained slides
by a microdissection as described previously (Lee et al, 1999),
whereas for the leukaemia non-fixed fresh bone marrows were
directly used. Because the AKT1 E17K mutation was detected in
the exon 3, genomic DNA each from tumour cells and
corresponding normal cells were amplified with one primer pair
covering the exon 3. Radioisotope ([
32P]dCTP) was incorporated
into the PCR products for detection by SSCP autoradiogram. After
SSCP, bands showing mobility shifts were re-amplified and
sequenced by a capillary automatic sequencer.
We also analysed AKT2 exon 3 and AKT3 exon 2 by the same
PCR-SSCP method. In this approach, we used 45 breast ductal
carcinomas, 45 colorectal adenocarcinomas, 45 gastric adeno-
carcinomas, 45 hepatocellular carcinomas, and 45 NSCLCs and 45
adulthood acute leukaemias.
RESULTS AND DISCUSSION
The PCR-SSCP analysis of the AKT1 exon 3 in the 731 cancers
identified aberrantly migrating bands in four breast cancers (4/93;
4.3%), but not in other cancers (Figure 1A). All of the four breast
cancers were invasive ductal carcinomas. DNA sequence analysis
revealed that the aberrant bands represented an identical mutation
(c.49G4A (p.E17K)) (Figure 1B). None of the normal samples
from the patients with the AKT1 E17K mutation showed evidence
of mutation by the SSCP, indicating that the mutations had risen
somatically. We also confirm the mutation by a direct DNA
sequencing in the four breast cancers (data not shown). In
addition, we performed direct DNA sequencing analyses for the
AKT1 E17K mutation in 120 cases of the cancers and found no
additional AKT1 E17K mutation in the cancers (data not shown).
Next, we attempted to find out the corresponding mutation of
AKT1 E17K in both AKT2 and AKT3 genes. However, the SSCP
from the tumours did not reveal any aberrantly migrating band
compared with the wild-type bands from the normal tissues (data
not shown). We repeated the experiments twice, including tissue
microdissection, PCR, SSCP and DNA sequencing analysis to
ensure the specificity of the results and found that the data were
consistent.
Because the previous study showed modest incidences of AKT1
E17K mutation (up to 8.2%) in a wide range of the cancers
(Carpten et al, 2007), we expected to detect comparable AKT1
E17K mutations in our cancer specimens. However, we detected
the AKT1 E17K mutation in the breast cancers (4.3%), but not in
other cancers. Statistically, there is no difference of the AKT1 E17K
mutation frequency in the breast cancers between the previous
study and our study (Fisher’s exact test, P¼0.253). By contrast,
there is a significant difference of the AKT1 E17K mutation
frequency in the colorectal cancers between the previous study and
our study (Fisher’s exact test, P¼0.034), suggesting a possibility
that a racial difference might exist. However, because the previous
reports did not describe the ethnicity of the patients (Carpten et al,
2007), it is not possible to conclude whether the difference arose
from a racial difference. Together, these data suggest that the AKT1
E17K mutation may be rare in common human cancers besides
breast cancers. Also we found neither AKT2 nor AKT3 mutation in
the corresponding sequences to the AKT1 E17K, indicating that
mutational alteration of neither AKT2 nor AKT3 contributes to
cancer development.
Because the most impressive examples of recent cancer
therapies target activated kinases by genetic alterations, cancer
researches have focused on evaluating kinases as promising
molecular targets for cancer treatment (Druker et al, 2001;
Fukuoka et al, 2003; Gschwind et al, 2004; Paez et al, 2004). The
discovery of the AKT1 E17K mutation in cancers raised a
possibility to treat cancers by targeting the mutated AKT1.
However, our data confirm the earlier data only in breast cancers,
but not in other types of common cancers. Therefore, the present
study suggested that the AKT1 E17K mutation should further be
analysed in a wider range of cancers.
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Figure 1 Representative data on AKT1 E17K mutation in the cancers. (A) The PCR products of the exon 3 from breast cancers were visualised on SSCP.
The arrows indicate aberrant bands as compared with the wild-type bands. (B) One of the aberrant bands on the SSCP was sequenced. The boxes indicate
nucleotide changes in the tumour DNA as compared with normal tissue DNA.
AKT1 E17K mutation in cancers
MS Kim et al
1534
British Journal of Cancer (2008) 98(9), 1533–1535 & 2008 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sREFERENCES
Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, Hostetter G,
B o g u s l a w s k iS ,M o s e sT Y ,S a v a g eS ,U h l i kM ,L i nA ,D uJ ,Q i a nY W ,
Zeckner DJ, Tucker-Kellogg G, Touchman J, Patel K, Mousses S, Bittner M,
Schevitz R, Lai MH, Blanchard KL, Thomas JE (2007) A transforming mutation
in the pleckstrin homology domain of AKT1 in cancer. Nature 448: 439–444
Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM
(1999) Activation of nitric oxide synthase in endothelial cells by
Akt-dependent phosphorylation. Nature 399: 601–605
Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM,
Capdeville R, Talpaz M (2001) Activity of a specific inhibitor of the BCR-
ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and
acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl
J Med 344: 1038–1042
Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY,
Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T,
Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A,
Dong RP, Baselga J (2003) Multi-institutional randomized phase II trial
of gefitinib for previously treated patients with advanced non-small-cell
lung cancer. J Clin Oncol 21: 2237–2246
Gschwind A, Fischer OM, Ullrich A (2004) The discovery of receptor
tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 4: 361–370
Khwaja A (1999) Akt is more than just a Bad kinase. Nature 401: 33–34
Lee SH, Shin MS, Park WS, Kim SY, Kim HS, Han JY, Park GS, Dong SM,
Pi JH, Kim CS, Kim SH, Lee JY, Yoo NJ (1999) Alterations of Fas (Apo-1/
CD95) gene in non-small cell lung cancer. Oncogene 18: 3754–3760
Mende I, Malstrom S, Tsichlis PN, Vogt PK, Aoki M (2001) Oncogenic
transformation induced by membrane-targeted Akt2 and Akt3. Oncogene
20: 4419–4423
Muise-Helmericks RC, Grimes HL, Bellacosa A, Malstrom SE, Tsichlis PN,
Rosen N (1998) Cyclin D expression is controlled post-transcriptionally
via a phosphatidylinositol 3-kinase/Akt-dependent pathway. J Biol Chem
273: 29864–29872
Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB (1999)
NF-kappaB activation by tumour necrosis factor requires the Akt serine-
threonine kinase. Nature 401: 82–85
Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P,
Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ,
Sellers WR, Johnson BE, Meyerson M (2004) EGFR mutations in lung
cancer: correlation with clinical response to gefitinib therapy. Science
304: 1497–1500
Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H,
Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW,
Vogelstein B, Velculescu VE (2004) High frequency of mutations of the
PIK3CA gene in human cancers. Science 304: 554
Testa JR, Bellacosa A (2001) AKT plays a central role in tumorigenesis. Proc
Natl Acad Sci USA 98: 10983–10985
Wei L, Yang Y, Yu Q (2001) Tyrosine kinase-dependent, phosphatidylino-
sitol 30-kinase, and mitogen-activated protein kinase-independent
signaling pathways prevent lung adenocarcinoma cells from anoikis.
Cancer Res 61: 2439–2444
AKT1 E17K mutation in cancers
MS Kim et al
1535
British Journal of Cancer (2008) 98(9), 1533–1535 & 2008 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
s